Mayne Pharma Group Limited
Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women's health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women's Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract developmen… Read more
Market Cap & Net Worth: Mayne Pharma Group Limited (MAYNF)
Mayne Pharma Group Limited (PINK:MAYNF) has a market capitalization of $340.01 Million ($340.01 Million) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #15473 globally and #6077 in its home market, demonstrating a -5.42% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Mayne Pharma Group Limited's stock price $4.19 by its total outstanding shares 81245827 (81.25 Million).
Mayne Pharma Group Limited Market Cap History: 2015 to 2025
Mayne Pharma Group Limited's market capitalization history from 2015 to 2025. Data shows growth from $82.14 Million to $340.01 Million (20.49% CAGR).
Mayne Pharma Group Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Mayne Pharma Group Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.83x
Mayne Pharma Group Limited's market cap is 0.83 times its annual revenue
0.29x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $78.81 Million | $266.19 Million | $37.35 Million | 0.30x | 2.11x |
| 2017 | $44.66 Million | $571.74 Million | $88.57 Million | 0.08x | 0.50x |
| 2018 | $45.73 Million | $529.14 Million | -$133.98 Million | 0.09x | N/A |
| 2019 | $24.86 Million | $523.96 Million | -$280.87 Million | 0.05x | N/A |
| 2020 | $21.53 Million | $456.60 Million | -$92.79 Million | 0.05x | N/A |
| 2021 | $16.90 Million | $400.32 Million | -$208.42 Million | 0.04x | N/A |
| 2022 | $10.16 Million | $157.15 Million | -$209.48 Million | 0.06x | N/A |
| 2023 | $345.29 Million | $183.59 Million | $117.25 Million | 1.88x | 2.94x |
| 2024 | $276.24 Million | $388.15 Million | -$174.23 Million | 0.71x | N/A |
| 2025 | $340.01 Million | $408.10 Million | -$93.84 Million | 0.83x | N/A |
Competitor Companies of MAYNF by Market Capitalization
Companies near Mayne Pharma Group Limited in the global market cap rankings as of March 19, 2026.
Key companies related to Mayne Pharma Group Limited by market ranking:
- McKesson Corporation (NYSE:MCK): Ranked #165 globally with a market cap of $115.21 Billion USD.
- Cencora Inc. (NYSE:COR): Ranked #350 globally with a market cap of $62.31 Billion USD.
- Cardinal Health Inc (NYSE:CAH): Ranked #430 globally with a market cap of $50.81 Billion USD.
- Sigma Healthcare Limited (OTCGREY:SIGGF): Ranked #1462 globally with a market cap of $12.16 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | McKesson Corporation | NYSE:MCK | $115.21 Billion | $941.89 |
| #350 | Cencora Inc. | NYSE:COR | $62.31 Billion | $334.71 |
| #430 | Cardinal Health Inc | NYSE:CAH | $50.81 Billion | $216.36 |
| #1462 | Sigma Healthcare Limited | OTCGREY:SIGGF | $12.16 Billion | $1.88 |
Mayne Pharma Group Limited Historical Marketcap From 2015 to 2025
Between 2015 and today, Mayne Pharma Group Limited's market cap moved from $82.14 Million to $ 340.01 Million, with a yearly change of 20.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $340.01 Million | +23.09% |
| 2024 | $276.24 Million | -20.00% |
| 2023 | $345.29 Million | +3300.00% |
| 2022 | $10.16 Million | -39.90% |
| 2021 | $16.90 Million | -21.51% |
| 2020 | $21.53 Million | -13.40% |
| 2019 | $24.86 Million | -45.64% |
| 2018 | $45.73 Million | +2.40% |
| 2017 | $44.66 Million | -43.33% |
| 2016 | $78.81 Million | -4.06% |
| 2015 | $82.14 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Mayne Pharma Group Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $340.01 Million USD |
| MoneyControl | $340.01 Million USD |
| MarketWatch | $340.01 Million USD |
| marketcap.company | $340.01 Million USD |
| Reuters | $340.01 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.